Tumor Response

Studied in DESTINY-Gastric01,

Tumor response and disease control rates for ENHERTU and irinotecan or paclitaxel

ENHERTU: Best Percent Change From Baseline in the Sum of Longest Diameters of Measurable Tumors (Exploratory Endpoint)2,a

Waterfall plot for ENHERTU showing the best percent change in baseline in the sum of longest diameters of measurable tumors. Waterfall plot for ENHERTU showing the best percent change in baseline in the sum of longest diameters of measurable tumors.
  • 84.1% disease control rate (DCR) with ENHERTU (n=106/126)5,c

Irinotecan or Paclitaxel: Best Percent Change From Baseline in the Sum of Longest Diameters of Measurable Tumors (Exploratory Endpoint)2,a

Waterfall plot for irinotecan or paclitaxel showing the best percent change in baseline in the sum of longest diameters of measurable tumors. Waterfall plot for irinotecan or paclitaxel showing the best percent change in baseline in the sum of longest diameters of measurable tumors.
  • 61.3% DCR with irinotecan or paclitaxel (n=38/62)5,c

aThe analyses included patients who had both baseline and postbaseline target-lesion assessments according to ICR.

bSix patients (2 in the ENHERTU arm and 4 in the irinotecan or paclitaxel arm) were excluded from this analysis because they did not undergo postbaseline tumor assessment.2

cDCR=CR+PR+SD.5

  • DESTINY-Gastric01 studied 188 adult patients with HER2+ aGC who had received ≥2 prior lines of treatment, including a trastuzumab-based regimen
Ready to learn more about ENHERTU?

CR, complete response; DCR, disease control rate; ICR, independent central review; PR, partial response; SD, stable disease.